JP2018529320A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529320A5 JP2018529320A5 JP2018505723A JP2018505723A JP2018529320A5 JP 2018529320 A5 JP2018529320 A5 JP 2018529320A5 JP 2018505723 A JP2018505723 A JP 2018505723A JP 2018505723 A JP2018505723 A JP 2018505723A JP 2018529320 A5 JP2018529320 A5 JP 2018529320A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- seq
- cell
- cancer
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562201289P | 2015-08-05 | 2015-08-05 | |
| US62/201,289 | 2015-08-05 | ||
| GB1513921.5 | 2015-08-06 | ||
| GBGB1513921.5A GB201513921D0 (en) | 2015-08-05 | 2015-08-06 | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| PCT/EP2016/068727 WO2017021527A2 (en) | 2015-08-05 | 2016-08-05 | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020191407A Division JP7142957B2 (ja) | 2015-08-05 | 2020-11-18 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018529320A JP2018529320A (ja) | 2018-10-11 |
| JP2018529320A5 true JP2018529320A5 (enExample) | 2019-09-12 |
| JP6884752B2 JP6884752B2 (ja) | 2021-06-09 |
Family
ID=54200350
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018505723A Expired - Fee Related JP6884752B2 (ja) | 2015-08-05 | 2016-08-05 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020191407A Active JP7142957B2 (ja) | 2015-08-05 | 2020-11-18 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2022142129A Pending JP2022191218A (ja) | 2015-08-05 | 2022-09-07 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2024215091A Pending JP2025038025A (ja) | 2015-08-05 | 2024-12-10 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020191407A Active JP7142957B2 (ja) | 2015-08-05 | 2020-11-18 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2022142129A Pending JP2022191218A (ja) | 2015-08-05 | 2022-09-07 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2024215091A Pending JP2025038025A (ja) | 2015-08-05 | 2024-12-10 | 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Country Status (36)
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2508923A (en) * | 2012-12-17 | 2014-06-18 | Bombardier Transp Gmbh | Inductive power transfer system having inductive sensing array |
| HRP20211852T1 (hr) | 2013-08-05 | 2022-03-18 | Immatics Biotechnologies Gmbh | Nova imunoterapija protiv nekoliko tumora, poput raka pluća, uključujući nsclc |
| GB201513921D0 (en) * | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| CN108350005B (zh) | 2015-08-05 | 2024-02-06 | 卫材R&D管理有限公司 | 用于制备均一低聚物的手性试剂 |
| MY198087A (en) | 2015-10-05 | 2023-07-31 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| KR102883915B1 (ko) | 2015-12-16 | 2025-11-18 | 시애틀 프로젝트 코포레이션 | 신생항원 동정, 제조, 및 용도 |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| AU2018269370B2 (en) | 2017-05-16 | 2025-06-05 | The Johns Hopkins University | Manabodies and methods of using |
| DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| PT3428194T (pt) | 2017-07-14 | 2021-11-18 | Immatics Biotechnologies Gmbh | Molécula de polipéptido com especificidade dupla melhorada |
| WO2019075112A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS |
| KR20260008173A (ko) | 2017-11-22 | 2026-01-15 | 시애틀 프로젝트 코포레이션 | 신생항원에 대한 접합 에피토프 제시 감소 |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| JP7470640B2 (ja) | 2018-02-09 | 2024-04-18 | イマティクス ユーエス，アイエヌシー． | Ｔ細胞を製造する方法 |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| CA3136405A1 (en) * | 2018-06-01 | 2019-12-05 | Geneoscopy, Inc. | Detection method for cancer using rna biomarkers |
| US10925947B2 (en) | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| TW202019955A (zh) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
| US11945850B2 (en) | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
| TW202024121A (zh) | 2018-09-18 | 2020-07-01 | 德商英麥提克生物技術股份有限公司 | A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法 |
| WO2020167894A1 (en) * | 2019-02-12 | 2020-08-20 | Vanderbilt University | Polypeptides for restoring endothelial function and methods of use thereof |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| MA56036A (fr) | 2019-05-27 | 2022-04-06 | Immatics Us Inc | Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive |
| US20200384028A1 (en) | 2019-06-06 | 2020-12-10 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| IL296881A (en) * | 2020-04-14 | 2022-12-01 | Universit? De Montr?Al | New antigens specific for acute myeloid leukemia (aml) and their uses |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| EP4255474A4 (en) * | 2020-12-07 | 2025-06-18 | Iogenetics, LLC. | PERSONALIZED IMMUNOTHERAPIES |
| PE20250846A1 (es) | 2020-12-31 | 2025-03-21 | Immatics Us Inc | Polipeptidos cd8, composiciones y metodos de uso de estos |
| BR112023022975A2 (pt) | 2021-05-05 | 2024-01-23 | Immatics Biotechnologies Gmbh | Polipeptídeos de ligação ao antígeno bma031 melhorados |
| EP4113120A1 (en) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| CN113527435B (zh) * | 2021-07-14 | 2022-06-07 | 呈诺再生医学科技(珠海横琴新区)有限公司 | 对前列腺癌细胞特异性识别的新型多肽及其衍生物与应用 |
| JP2024534825A (ja) | 2021-08-24 | 2024-09-26 | イマティクス ユーエス，アイエヌシー． | 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択 |
| WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| EP4408468A4 (en) | 2021-09-28 | 2025-07-02 | Frontaim Biomedicines Inc | MULTIPLE FORMATS OF MOLECULAR COMPLEXES |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| IL316515A (en) | 2022-04-28 | 2024-12-01 | Immatics Us Inc | Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2025137979A1 (zh) * | 2023-12-28 | 2025-07-03 | 祺安（广州）生物科技有限公司 | 特异性多肽在制备治疗、预防前列腺癌的药物中的应用 |
| WO2026030428A2 (en) * | 2024-08-01 | 2026-02-05 | Regeneron Pharmaceuticals, Inc. | Prostate-specific antigen peptides and uses thereof |
| WO2026096743A1 (en) | 2024-10-30 | 2026-05-07 | Immatics US, Inc. | Methods for gamma delta t cells manufacturing |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1037656A (en) | 1911-11-28 | 1912-09-03 | Thomas F Loughran | Prorating-weir. |
| US1178658A (en) | 1914-06-11 | 1916-04-11 | United Shoe Machinery Ab | Gripper mechanism for pulling-over machines. |
| US1165315A (en) | 1914-10-31 | 1915-12-21 | William F Cameron | Governor-valve. |
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| DK171727B1 (da) | 1978-12-22 | 1997-04-14 | Biogen Inc | Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| US6037135A (en) | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
| US9340577B2 (en) * | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
| JP3908271B2 (ja) | 1993-03-05 | 2007-04-25 | エピミューン，インコーポレイティド | Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用 |
| DE69420137T2 (de) | 1993-06-03 | 1999-12-23 | Therapeutic Antibodies, Inc. | Herstellung von antikörperfragmenten |
| US20040157780A1 (en) * | 1993-11-29 | 2004-08-12 | Epimmune Inc. | CTL inducing peptides from c-erb2 (HER-2/neu) |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US6824993B2 (en) * | 1995-06-06 | 2004-11-30 | Human Genome Sciences, Inc. | Antibodies that bind human prostate specific G-protein receptor HPRAJ70 |
| CA2243235C (en) | 1996-01-17 | 2010-08-10 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| DE19623825C1 (de) | 1996-06-14 | 1998-01-08 | Rottefella As | Langlauf- oder Tourenskibindung |
| AU4086397A (en) * | 1996-09-06 | 1998-03-26 | Centocor Inc. | Monoclonal antibodies specific for prostate specific antigen and methods of detecting prostate specific antigen |
| US7008772B1 (en) * | 1997-02-25 | 2006-03-07 | Corixa Corporation | Compounds for immunodiagnosis of prostate cancer and methods for their use |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US20070020327A1 (en) * | 1998-11-10 | 2007-01-25 | John Fikes | Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions |
| AU7994200A (en) | 1999-10-04 | 2001-05-10 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
| US7361338B2 (en) | 1999-10-05 | 2008-04-22 | Agensys, Inc. | Methods to inhibit growth of prostate cancer cells |
| AU7753700A (en) * | 1999-10-07 | 2001-05-10 | Schering Aktiengesellschaft | Dna encoding prost 07 polypeptide |
| EP1230364A2 (en) * | 1999-11-12 | 2002-08-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| WO2001051633A2 (en) * | 2000-01-14 | 2001-07-19 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US20020081590A1 (en) | 2000-02-04 | 2002-06-27 | Aeomica, Inc. | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
| US20030219806A1 (en) * | 2000-02-22 | 2003-11-27 | Millennium Pharmaceuticals, Inc. | Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor |
| IL151860A0 (en) | 2000-03-27 | 2003-04-10 | Technion Res & Dev Foundation | Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| EP1311673A2 (en) * | 2000-03-27 | 2003-05-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| WO2001074904A2 (en) | 2000-03-31 | 2001-10-11 | Curagen Corporation | G-protein coupled receptors and nucleic acids encoding same |
| US7834146B2 (en) * | 2000-05-08 | 2010-11-16 | Monsanto Technology Llc | Recombinant polypeptides associated with plants |
| AU7524601A (en) | 2000-06-05 | 2001-12-17 | Sunol Molecular Corp | T cell receptor fusions and conjugates and methods of use thereof |
| GB0015722D0 (en) * | 2000-06-27 | 2000-08-16 | Smithkline Beecham Sa | Vaccine |
| US7199229B2 (en) * | 2000-08-11 | 2007-04-03 | Mount Sinai Hospital | Kallikrein gene |
| CA2425648A1 (en) * | 2000-10-19 | 2002-04-19 | Epimmune Inc. | Hla class i and ii binding peptides and their uses |
| US7048931B1 (en) * | 2000-11-09 | 2006-05-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| AU2002246708A1 (en) * | 2000-12-15 | 2002-08-12 | Agensys, Inc. | Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer |
| US20030109692A1 (en) * | 2000-12-18 | 2003-06-12 | Muralidhara Padigaru | Novel proteins and nucleic acids encoding same |
| AUPR402201A0 (en) * | 2001-03-27 | 2001-04-26 | Queensland University Of Technology | Polynucleotides and polypeptides linked to cancer and/or benign tumours |
| JP2005508157A (ja) | 2001-08-31 | 2005-03-31 | アジェンシス，インコーポレイテッド | 癌の処置および検出において有用な２０５ｐ１ｂ５との名称の核酸および対応するタンパク質 |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| EP1485075A4 (en) | 2002-02-20 | 2006-04-26 | Dyax Corp | MHC-PEPTIDE COMPLEX BINDING LIGANDS |
| DE10215321A1 (de) * | 2002-04-02 | 2003-10-23 | Metagen Pharmaceuticals Gmbh | Trp-p8 Splice Varianten und regulatorische RNA |
| BR0313154A (pt) * | 2002-08-12 | 2005-08-02 | Council The Queensland Inst Of | Novos lipopeptìdeos imunogênicos que compreendem epitopos de célula t-helper e de célula b |
| EP2181595A1 (en) | 2002-08-16 | 2010-05-05 | Yeda Research And Development Company Ltd. | Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines |
| US20060079453A1 (en) | 2002-10-03 | 2006-04-13 | John Sidney | Hla binding peptides and their uses |
| NZ539225A (en) | 2002-10-09 | 2006-09-29 | Avidex Ltd | Single chain recombinant T cell receptors |
| AU2003276403B2 (en) | 2002-11-09 | 2010-04-15 | Adaptimmune Limited | T cell receptor display |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| GB0318096D0 (en) * | 2003-08-01 | 2003-09-03 | Queen Mary & Westfield College | Vaccine |
| US20050053988A1 (en) | 2003-08-08 | 2005-03-10 | The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Gene expressed in breast cancer and methods of use |
| US20090298108A1 (en) | 2005-02-28 | 2009-12-03 | Joachim Schultz | Method for Identifying PDE11 Modulators |
| WO2006098464A1 (ja) * | 2005-03-14 | 2006-09-21 | Link Genomics, Inc. | 前立腺がんの診断方法 |
| EP1806358B1 (en) | 2005-09-05 | 2010-03-17 | Immatics Biotechnologies GmbH | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| WO2007053570A2 (en) | 2005-10-31 | 2007-05-10 | Janssen Pharmaceutica N.V. | A polypeptide complex of trpm8 and calmodulin and its uses thereof |
| US20130332133A1 (en) * | 2006-05-11 | 2013-12-12 | Ramot At Tel Aviv University Ltd. | Classification of Protein Sequences and Uses of Classified Proteins |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| CA2723143A1 (en) | 2008-05-01 | 2009-11-05 | Martin G. Sanda | Methods and compositions for prostate cancer immunotherapy |
| RS53872B2 (sr) | 2008-05-14 | 2018-06-29 | Immatics Biotechnologies Gmbh | Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana |
| US20110318380A1 (en) * | 2008-10-01 | 2011-12-29 | Dako Denmark A/S | MHC Multimers in Cancer Vaccines and Immune Monitoring |
| RS53782B1 (sr) * | 2008-10-01 | 2015-06-30 | Immatics Biotechnologies Gmbh | Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera |
| WO2010102157A1 (en) | 2009-03-04 | 2010-09-10 | The Regents Of The University Of California | Molecular predictors of biological response to a cenpe inhibitor in cancer |
| WO2011119484A1 (en) * | 2010-03-23 | 2011-09-29 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| WO2013040142A2 (en) * | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| CN103282384A (zh) * | 2010-07-15 | 2013-09-04 | 奥列格·伊里奇·爱泼斯坦 | 复合药物组合物以及对泌尿生殖系统障碍进行治疗的方法 |
| US20120121592A1 (en) * | 2010-10-13 | 2012-05-17 | Baylor Research Institute | Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells |
| WO2012056407A1 (en) | 2010-10-26 | 2012-05-03 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
| SG191154A1 (en) * | 2010-12-14 | 2013-07-31 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| WO2014047085A2 (en) | 2012-09-20 | 2014-03-27 | Rongfu Wang | Prostate-specific tumor antigen and uses thereof |
| EP2917388B1 (en) | 2012-11-08 | 2016-10-05 | Roche Diagnostics GmbH | Nucleic acids encoding chimeric polypeptides for library screening |
| EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
| TWI777194B (zh) | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（一） |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| WO2016138362A1 (en) * | 2015-02-26 | 2016-09-01 | The Board Of Trustees Of The University Of Arkansas | Treatment vaccine for prostate cancer |
| RU2719033C2 (ru) * | 2015-04-23 | 2020-04-16 | Нантомикс, Ллс | Способ получения фармацевтического агента для иммунотерапии рака |
| GB201513921D0 (en) * | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| GB201520566D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| BR112019028280A2 (pt) * | 2017-07-04 | 2020-07-14 | Curevac Ag | moléculas de ácido nucleico |
| CA3202176A1 (en) | 2020-12-14 | 2022-06-23 | Michael Steven ROONEY | Tissue-specific antigens for cancer immunotherapy |
-
2015
- 2015-08-06 GB GBGB1513921.5A patent/GB201513921D0/en not_active Ceased
-
2016
- 2016-08-04 AR ARP160102395A patent/AR105817A1/es not_active Application Discontinuation
- 2016-08-05 DK DK16750766.4T patent/DK3331900T3/da active
- 2016-08-05 RS RS20210446A patent/RS61713B1/sr unknown
- 2016-08-05 PL PL16750766T patent/PL3331900T3/pl unknown
- 2016-08-05 JP JP2018505723A patent/JP6884752B2/ja not_active Expired - Fee Related
- 2016-08-05 TW TW105124943A patent/TWI829618B/zh not_active IP Right Cessation
- 2016-08-05 MA MA053452A patent/MA53452A/fr unknown
- 2016-08-05 ES ES16750766T patent/ES2862400T3/es active Active
- 2016-08-05 MD MDE20180586T patent/MD3331900T2/ro not_active IP Right Cessation
- 2016-08-05 CR CR20200432A patent/CR20200432A/es unknown
- 2016-08-05 MX MX2018001421A patent/MX2018001421A/es unknown
- 2016-08-05 MA MA053680A patent/MA53680A/fr unknown
- 2016-08-05 EP EP16750766.4A patent/EP3331900B1/en active Active
- 2016-08-05 EP EP20216870.4A patent/EP3842446A1/en not_active Withdrawn
- 2016-08-05 KR KR1020187005514A patent/KR102943979B1/ko active Active
- 2016-08-05 LT LTEP16750766.4T patent/LT3331900T/lt unknown
- 2016-08-05 MA MA41879A patent/MA41879A1/fr unknown
- 2016-08-05 BR BR112018001687-0A patent/BR112018001687A2/pt not_active Application Discontinuation
- 2016-08-05 HR HRP20210709TT patent/HRP20210709T8/hr unknown
- 2016-08-05 CR CR20200433A patent/CR20200433A/es unknown
- 2016-08-05 SG SG10202001660YA patent/SG10202001660YA/en unknown
- 2016-08-05 MY MYPI2020006864A patent/MY200281A/en unknown
- 2016-08-05 PE PE2018000178A patent/PE20180695A1/es unknown
- 2016-08-05 CN CN202111376484.6A patent/CN114395013A/zh active Pending
- 2016-08-05 EP EP23216403.8A patent/EP4324472A3/en active Pending
- 2016-08-05 SI SI201631144T patent/SI3331900T1/sl unknown
- 2016-08-05 PT PT167507664T patent/PT3331900T/pt unknown
- 2016-08-05 MY MYPI2020006865A patent/MY203318A/en unknown
- 2016-08-05 UA UAA201800448A patent/UA125816C2/uk unknown
- 2016-08-05 CR CR20200434A patent/CR20200434A/es unknown
- 2016-08-05 CR CR20200435A patent/CR20200435A/es unknown
- 2016-08-05 EA EA201890440A patent/EA201890440A1/ru unknown
- 2016-08-05 IL IL310078A patent/IL310078A/en unknown
- 2016-08-05 MY MYPI2018700247A patent/MY202812A/en unknown
- 2016-08-05 TW TW109124889A patent/TW202106702A/zh unknown
- 2016-08-05 AU AU2016303021A patent/AU2016303021B2/en not_active Ceased
- 2016-08-05 EP EP20216899.3A patent/EP3854801A3/en not_active Withdrawn
- 2016-08-05 TW TW112150529A patent/TW202415673A/zh unknown
- 2016-08-05 PE PE2023002284A patent/PE20250557A1/es unknown
- 2016-08-05 CR CR20180074A patent/CR20180074A/es unknown
- 2016-08-05 CR CR20200431A patent/CR20200431A/es unknown
- 2016-08-05 WO PCT/EP2016/068727 patent/WO2017021527A2/en not_active Ceased
- 2016-08-05 MA MA46022A patent/MA46022B1/fr unknown
- 2016-08-05 CA CA2994771A patent/CA2994771C/en active Active
- 2016-08-05 CN CN201680045204.4A patent/CN107849107A/zh active Pending
- 2016-08-05 CA CA3110633A patent/CA3110633A1/en active Pending
- 2016-08-05 CA CA3110640A patent/CA3110640A1/en active Pending
- 2016-08-05 HU HUE16750766A patent/HUE053657T2/hu unknown
- 2016-08-05 US US15/229,970 patent/US9908920B2/en not_active Expired - Fee Related
-
2017
- 2017-06-29 US US15/637,906 patent/US9993539B2/en active Active
- 2017-06-29 US US15/638,072 patent/US10155032B2/en active Active
- 2017-12-21 US US15/849,878 patent/US10500259B2/en active Active
-
2018
- 2018-01-24 ZA ZA2018/00513A patent/ZA201800513B/en unknown
- 2018-01-25 PH PH12018500189A patent/PH12018500189A1/en unknown
- 2018-02-01 MX MX2021015933A patent/MX2021015933A/es unknown
- 2018-02-04 IL IL257331A patent/IL257331A/en unknown
- 2018-02-05 CL CL2018000324A patent/CL2018000324A1/es unknown
- 2018-02-27 CO CONC2018/0002202A patent/CO2018002202A2/es unknown
- 2018-08-10 US US16/100,498 patent/US10383930B2/en active Active
- 2018-10-05 US US16/153,294 patent/US10238727B2/en active Active
- 2018-12-05 US US16/210,330 patent/US10376568B2/en active Active
-
2019
- 2019-04-16 US US16/385,225 patent/US10478480B2/en active Active
- 2019-04-16 US US16/385,221 patent/US10449238B2/en active Active
- 2019-07-10 US US16/507,375 patent/US10532091B1/en active Active
- 2019-08-27 US US16/552,873 patent/US10799569B2/en active Active
-
2020
- 2020-06-29 US US16/915,465 patent/US11058754B2/en active Active
- 2020-09-10 US US17/017,281 patent/US11065315B2/en not_active Expired - Fee Related
- 2020-11-18 JP JP2020191407A patent/JP7142957B2/ja active Active
-
2021
- 2021-02-26 CY CY20211100164T patent/CY1123854T1/el unknown
- 2021-04-01 AU AU2021202059A patent/AU2021202059B2/en not_active Ceased
- 2021-04-01 AU AU2021202060A patent/AU2021202060B2/en not_active Ceased
- 2021-04-01 AU AU2021202058A patent/AU2021202058B2/en not_active Ceased
- 2021-04-01 AU AU2021202057A patent/AU2021202057B2/en not_active Ceased
- 2021-04-01 AU AU2021202056A patent/AU2021202056B2/en not_active Ceased
- 2021-05-14 US US17/320,938 patent/US11826409B2/en active Active
- 2021-05-14 US US17/320,929 patent/US11786584B2/en active Active
- 2021-05-14 US US17/320,878 patent/US20210275653A1/en not_active Abandoned
- 2021-06-11 CL CL2021001544A patent/CL2021001544A1/es unknown
- 2021-06-11 CL CL2021001545A patent/CL2021001545A1/es unknown
- 2021-06-11 CL CL2021001543A patent/CL2021001543A1/es unknown
- 2021-06-11 CL CL2021001542A patent/CL2021001542A1/es unknown
- 2021-06-30 CL CL2021001744A patent/CL2021001744A1/es unknown
-
2022
- 2022-01-14 US US17/576,067 patent/US12102670B2/en active Active
- 2022-01-14 US US17/576,185 patent/US12076381B2/en active Active
- 2022-01-21 US US17/581,054 patent/US20220143163A1/en not_active Abandoned
- 2022-01-21 US US17/581,049 patent/US12097249B2/en active Active
- 2022-01-28 US US17/587,536 patent/US12144852B2/en active Active
- 2022-01-28 US US17/587,474 patent/US12180259B2/en active Active
- 2022-02-04 US US17/592,573 patent/US20220152175A1/en not_active Abandoned
- 2022-09-07 JP JP2022142129A patent/JP2022191218A/ja active Pending
- 2022-11-21 CL CL2022003264A patent/CL2022003264A1/es unknown
-
2023
- 2023-07-13 AU AU2023204661A patent/AU2023204661A1/en not_active Abandoned
- 2023-08-17 US US18/451,216 patent/US20240016908A1/en active Pending
- 2023-09-22 AU AU2023233214A patent/AU2023233214A1/en not_active Abandoned
-
2024
- 2024-12-10 JP JP2024215091A patent/JP2025038025A/ja active Pending